Lecture 3: Introduction to confounding (part 1)

Slides:



Advertisements
Similar presentations
Epidemiologic Study Designs Clinical Studies & Objective Medicine
Advertisements

External validity: to what populations do our study results apply?
M2 Medical Epidemiology
Deriving Biological Inferences From Epidemiologic Studies.
EPID Introduction to Analysis and Interpretation of HIV/STD Data Confounding Manya Magnus, Ph.D. Summer 2001 adapted from M. O’Brien and P. Kissinger.
Chance, bias and confounding
Confounding And Interaction Dr. L. Jeyaseelan Department Of Biostatistics CMC, Vellore.
THREE CONCEPTS ABOUT THE RELATIONSHIPS OF VARIABLES IN RESEARCH
Designing Clinical Research 2009 Confounding and Causal Inference Warren Browner.
Confounding and effect modification Manish Chaudhary BPH(IOM, TU), MPH(BPKIHS)
INTRODUCTION TO EPIDEMIOLO FOR POME 105. Lesson 3: R H THEKISO:SENIOR PAT TIME LECTURER INE OF PRESENTATION 1.Epidemiologic measures of association 2.Study.
Unit 6: Standardization and Methods to Control Confounding.
Gerstman Case-Control Studies 1 Epidemiology Kept Simple Section 11.5 Case-Control Studies.
1 Journal Club Alcohol, Other Drugs, and Health: Current Evidence January–February 2014.
Tim Wiemken PhD MPH CIC Assistant Professor Division of Infectious Diseases University of Louisville, Kentucky Confounding.
Measures of Association
Amsterdam Rehabilitation Research Center | Reade Multiple regression analysis Analysis of confounding and effectmodification Martin van de Esch, PhD.
COMH7202: EPIDEMIOLOGY III – INTERMEDIATE CONCEPTS Confounding & Effect Modification
Introduction to confounding and DAGs
October 15. In Chapter 19: 19.1 Preventing Confounding 19.2 Simpson’s Paradox 19.3 Mantel-Haenszel Methods 19.4 Interaction.
Statistics for clinicians Biostatistics course by Kevin E. Kip, Ph.D., FAHA Professor and Executive Director, Research Center University of South Florida,
Case-control study Chihaya Koriyama August 17 (Lecture 1)
Design and Analysis of Clinical Study 2. Bias and Confounders Dr. Tuan V. Nguyen Garvan Institute of Medical Research Sydney, Australia.
Tim Wiemken PhD MPH CIC Assistant Professor Division of Infectious Diseases University of Louisville, Kentucky Confounding.
11/20091 EPI 5240: Introduction to Epidemiology Confounding: concepts and general approaches November 9, 2009 Dr. N. Birkett, Department of Epidemiology.
1 Multivariable Modeling. 2 nAdjustment by statistical model for the relationships of predictors to the outcome. nRepresents the frequency or magnitude.
Confounding and effect modification Epidemiology 511 W. A. Kukull November
Matching. Objectives Discuss methods of matching Discuss advantages and disadvantages of matching Discuss applications of matching Confounding residual.
Introduction to Biostatistics, Harvard Extension School, Fall, 2005 © Scott Evans, Ph.D.1 Contingency Tables.
(www).
Challenges to the Epidemiology of Aging: The REasons for Geographic And Racial Differences in Stroke Study George Howard, DrPH UAB School of Public Health.
Methodological quality assessment of observational studies Nicole Vogelzangs Department of Psychiatry & EMGO + institute.
Epidemiological Study Designs And Measures Of Risks (1)
Chapter 9: Case Control Studies Objectives: -List advantages and disadvantages of case-control studies -Identify how selection and information bias can.
The epidemiological tool-box
Study Designs Group Work
Chihaya Koriyama August 17 (Lecture 1)
Present: Disease Past: Exposure
Comparison of three Observational Analytical strategies
Lecture notes on epidemiological studies for undergraduates
Matched Case-Control Study
Epidemiological Methods
Epidemiology 503 Confounding.
Lecture 2: Bias Jeffrey E. Korte, PhD
Validity Generalization
دانشگاه علوم پزشکی بوشهر دانشکده بهداشت
Lecture 13: Case-control studies: introduction to matching
Lecture 1: Fundamentals of epidemiologic study design and analysis
Jeffrey E. Korte, PhD BMTRY 747: Foundations of Epidemiology II
Coffee drinking and leukocyte telomere length: A meta-analysis
Chapter 18 Cross-Tabulated Counts
BMTRY 747: Introduction Jeffrey E. Korte, PhD
Jeffrey E. Korte, PhD BMTRY 747: Foundations of Epidemiology II
Lecture 4: Introduction to confounding (part 2)
Hein Stigum courses DAGs intro, Answers Hein Stigum courses 28. nov. H.S.
Lecture 6: Introduction to effect modification (part 2)
Presenter: Wen-Ching Lan Date: 2018/03/28
Jeffrey E. Korte, PhD BMTRY 747: Foundations of Epidemiology II
Kanguk Samsung Hospital, Sungkyunkwan University
Jeffrey E. Korte, PhD BMTRY 747: Foundations of Epidemiology II
Epidemiology MPH 531 Analytic Epidemiology Case control studies
Measurements of Risk & Association …
Evaluating Effect Measure Modification
The Aga Khan University
Mendelian Randomization (Using genes to tell us about the environment)
Research Techniques Made Simple: Interpreting Measures of Association in Clinical Research Michelle Roberts PhD,1,2 Sepideh Ashrafzadeh,1,2 Maryam Asgari.
Dr Luis E Cuevas – LSTM Julia Critchley
Confounders.
Effect Modifiers.
Alcohol, Other Drugs, and Health: Current Evidence May–June 2019
Presentation transcript:

Lecture 3: Introduction to confounding (part 1) Jeffrey E. Korte, PhD BMTRY 747: Foundations of Epidemiology II Department of Public Health Sciences Medical University of South Carolina Spring 2015

Observational research Studies with no selection or information bias may still suffer from confounding Confounding is a type of bias Produces an observed association different from the “true” association you are looking for But confounding is different Does not result from a problem with study design or execution Reflects complex relationships among multiple factors: the reality of observational research The “web of causation”

Observational research Confounders may be known or unknown Known confounders might (or might not) be measured in your study To be a confounder, a factor must be associated with both the exposure and the outcome of interest.

Observational research Avoiding bias and confounding drives much of what we do in epidemiology Goal: to more fully understand the relationships between risk factors and health outcomes Could be: adjusted relationship (out of context) Could be: relationship in the context of other concurrent factors

Confounding variable exposure disease confounder

Confounding variable Produces a change in the observed association between exposure and disease Confounder may: Inflate the association (or cause an association to appear) Decrease the association (or cause it to vanish) This occurs because confounder is related to disease, and is distributed differently between exposure groups

Exchangeability The two comparison groups should theoretically be exchangeable with respect to all factors other than the exposure of interest This can only be achieved in a randomized controlled trial Lack of exchangeability leads to confounding

Example: alcohol and lung cancer (heavy drinkers) Dis Not dis Exp 31 369 400 No exp 79 1521 1600 110 1890 2000 RR=(31/400)/(79/1600)=1.6

Example: alcohol and lung cancer crude RR=(31/400)/(79/1600)=1.6 Dis Not dis Exp 1 99 100 No exp 9 891 900 10 990 1000 Dis Not dis Exp 30 270 300 No exp 70 630 700 100 900 1000 Non-smokers: RR=1.0 Smokers: RR=1.0

Example: alcohol and lung cancer Rates of heavy drinking: Smokers: 30% Non-smokers: 10% Rates of lung cancer: Smokers: 10% Non-smokers: 1% No association between alcohol and lung cancer, after stratifying by smoking status Conclusion: association is confounded by smoking

Smoking and lung cancer (same data, rearranged) Dis Not dis Exp 70 630 700 No exp 9 891 900 79 1521 1600 Dis Not dis Exp 30 270 300 No exp 1 99 100 31 369 400 Non-drinkers: RR=10 Drinkers: RR=10

Smoking and lung cancer (same data, rearranged) Dis Not dis Exp 100 900 1000 No exp 10 990 110 1890 2000 RR = ((100/1000) / (10/1000) = 10 Stratified associations are identical to crude association Conclusion: no confounding by alcohol drinking

Example: alcohol and lung cancer (heavy drinkers) Unadjusted: Alcohol-lung cancer RR=1.6 Smoking-lung cancer RR=10 Adjusted: Alcohol-lung cancer RR=1.0

Example: alcohol and lung cancer (heavy drinkers) Conclusion 1: Smoking is a confounder of alcohol-lung cancer association, because: Smoking is unevenly distributed between drinkers and non-drinkers, AND Smoking is a cause of lung cancer “unevenly distributed”: same thing as saying that smoking is associated with drinking

Example: alcohol and lung cancer (heavy drinkers) Conclusion 1: Smoking is a confounder of alcohol-lung cancer association, because: Smoking is unevenly distributed between drinkers and non-drinkers, AND Smoking is a cause of lung cancer “unevenly distributed”: same thing as saying that smoking is associated with drinking

Alcohol and lung cancer ? alcohol lung cancer

Alcohol and lung cancer X alcohol lung cancer smoking

Example: alcohol and lung cancer (heavy drinkers) Conclusion 2: Alcohol drinking is not a confounder of smoking-lung cancer association, because: Drinking is unevenly distributed between smokers and non-smokers, BUT Drinking is not a cause of lung cancer

Smoking and lung cancer ? smoking lung cancer

Smoking and lung cancer X alcohol

Example: alcohol and lung cancer (heavy drinkers) Conclusion 3: Confounding is not reciprocal in this case Smoking confounds alcohol-lung cancer association: Crude RR: 1.6 Stratified RRs: 1.0 in smokers, 1.0 in non-smokers But alcohol does not confound smoking-lung cancer association: Crude RR: 10.0 Stratified RRs: 10.0 in drinkers, 10.0 in non-drinkers

Example: alcohol and lung cancer (heavy drinkers) Conclusion 4: There is no effect modification Stratified RRs for alcohol-lung cancer: 1.0 in smokers, 1.0 in non-smokers Stratified RRs for smoking-lung cancer: 10.0 in drinkers, 10.0 in non-drinkers By the way, effect modification is always reciprocal (confounding can be reciprocal, but is not in this example)

Example: alcohol and lung cancer (heavy drinkers) Lung cancer rates: Smokers who drink: 30/300 = 10% Smokers who don’t drink: 70/700 = 10% Non-smokers who drink: 1/100 = 1% Non-smokers who don’t drink: 9/900 = 1%

Example: alcohol and lung cancer (heavy drinkers) How would this example look if the study had been a randomized controlled trial? With sufficient sample size, RCTs should be free of confounding Equal distribution of all risk factors between exposure groups (the only difference between the groups is the exposure: this is perfect exchangeability)

Example: alcohol and lung cancer (randomized controlled trial) Dis Not dis Exp 7 693 700 No exp 14 1386 1400 Dis Not dis Exp 30 270 300 No exp 60 540 600 Non-smokers: RR=1.0 Smokers: RR=1.0

Example: alcohol and lung cancer (randomized controlled trial) Dis Not dis Exp 37 963 1000 No exp 74 1926 2000 Relative risk: (37/1000) / (37/1000) =1.0

Example: alcohol and lung cancer (randomized controlled trial) Conclusion: no confounding Crude RR = (37/1000) / (37/1000) = 1.0 Stratified RRs: Smokers RR=1.0 Non-smokers RR=1.0 Adjusted RR has to be 1.0 weighted average of 1.0 and 1.0

Example: alcohol and lung cancer (heavy drinkers) How would this example look if the study had been a matched case-control study? Matching is another way to control confounding through study design Equal distribution of matched risk factors between cases and controls (confounding is impossible if the potential confounder is forced to be equally distributed)

Example: alcohol and lung cancer (matched case-control study) Dis Not dis Exp 70 140 No exp 630 1260 700 1400 Dis Not dis Exp 90 180 No exp 210 420 300 600 Non-smokers: OR=1.0 Smokers: OR=1.0

Example: alcohol and lung cancer (matched case-control study) Dis Not dis Exp 160 320 No exp 840 1680 1000 2000 Odds ratio: (160/840) / (160/840) = 1.0

Example: alcohol and lung cancer (matched case-control study) Conclusion: no confounding Crude OR = (160/840) / (160/840) = 1.0 Stratified ORs: Smokers RR=1.0 Non-smokers RR=1.0 Adjusted OR has to be 1.0 Weighted average of 1.0 and 1.0

Summary: how to control confounding Design Matching Randomized study Analysis Stratification Multivariate modeling

Caution: what if the confounder is on the causal pathway? (example 1) alcohol lung cancer ? smoking

Caution: what if the confounder is on the causal pathway? (example 2) # sexual partners cervical cancer ? HPV

Caution: what if the confounder is on the causal pathway? Discuss Schiffman et al 1993; JNCI 85(12):958-64 Discuss Safaeian et al 2010; JNCI 102(23):1794-1804